01:29 AM EDT, 09/17/2026 (MT Newswires) -- Roche (RO.SW) said Thursday that its late-stage study of Lunsumio combination therapy for relapsed or refractory follicular lymphoma met its primary endpoint at an interim analysis. The phase 3 Celestimo study evaluated Lunsumio plus lenalidomide against MabThera/Rituxan plus lenalidomide in patients who have received at least one prior line of treatment. The Lunsumio combination therapy showed statistically significant improvement in progression-free survival. Overall survival data were immature at the time of interim analysis. The safety profile remained in line with the known profiles of the individual study medicines, with no new safety signals identified. The drugmaker plans to submit the data to health authorities and present it at an upcoming medical meeting.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.